von Tobias Borgers | Jan. 10, 2024 | Boehringer
INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ — Boehringer Ingelheim and 3T Biosciences („3T“) today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and...
von Tobias Borgers | Dez. 21, 2023 | Boehringer
This webcast features: Athelney Woolnough, Director Business Development/Key Account Management BioXcellence, Franz Schuster, Strategy Implementation Manager Biopharma Austria, Cécile Brocard, Director of Downstream Development, Process Science RCV, Boehringer...
von Tobias Borgers | Dez. 21, 2023 | Boehringer
RealmFive, a leader in data connectivity and digital solutions based in Lincoln, Neb., has teamed up with Boehringer Ingelheim Animal Health, to commercialize next-generation technology-based solutions for advancing remote connectivity and herd health across the swine...
von Tobias Borgers | Dez. 14, 2023 | Boehringer
Oxford BioTherapeuticsBI 764532 was discovered using OBT’s proprietary OGAP® platform, the world’s largest, cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targetsOxford, UK, San Jose, Calif., 24th October 2023...
von Tobias Borgers | Dez. 7, 2023 | Boehringer
Ingelheim, Germany: SENVELGO® (velagliflozin oral solution) is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus SENVELGO® makes treating feline diabetes simple and convenient for both...
von Tobias Borgers | Nov. 23, 2023 | Boehringer
We have been using Genedata Biologics across our early biologics discovery operations for many years and are very excited to onboard the US-DMPK group as this is a major step towards having complete end-to-end digital tracking of all BI’s therapeutic candidates....
